A Multi-Center, Parallel-Group, Randomized, Double Blind, Adaptive Study Investigating the Safety and Efficacy of THR-184 in Patients at Increased Risk of Developing Cardiac Surgery Associated-Acute Kidney Injury (CSA-AKI)

Trial Profile

A Multi-Center, Parallel-Group, Randomized, Double Blind, Adaptive Study Investigating the Safety and Efficacy of THR-184 in Patients at Increased Risk of Developing Cardiac Surgery Associated-Acute Kidney Injury (CSA-AKI)

Completed
Phase of Trial: Phase II

Latest Information Update: 25 Apr 2017

At a glance

  • Drugs THR 184 (Primary)
  • Indications Acute kidney injury
  • Focus Therapeutic Use
  • Sponsors Thrasos Therapeutics
  • Most Recent Events

    • 29 Feb 2016 According to a Thrasos Therapeutics media release, full results of this study will be submitted for presentation at an upcoming scientific conference.
    • 29 Feb 2016 Top-line results published in a Thrasos Therapeutics media release.
    • 29 Feb 2016 According to a Thrasos Therapeutics media release, status changed from active, no longer recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top